• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Lifshitz Law PLLC Announces Investigations of APRN, RENB, ICPT

    9/30/23 7:00:00 PM ET
    $APRN
    $ICPT
    $RENB
    Catalog/Specialty Distribution
    Consumer Discretionary
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $APRN alert in real time by email

    NEW YORK, Sept. 30, 2023 (GLOBE NEWSWIRE) --

    Renovaro Biosciences, Inc. (NASDAQ:RENB)

    Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the merger of RENB and GEDi Cube Intl Ltd. Under the terms of the proposed transaction, GEDi Cube Intl Ltd. equity interests will be exchanged for shares of RENB common stock through a stock-for-stock acquisition.

    If you are a RENB investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at [email protected].

    Blue Apron Holdings, Inc. (NASDAQ:APRN)

    Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the sale of APRN to Wonder Group for $13.00 per share in cash.

    If you are an APRN investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at [email protected].

    Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT)

    Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the sale of ICPT to Alfasigma S.p.A for $19.00 per share in cash.

    If you are an ICPT investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at [email protected].

    ATTORNEY ADVERTISING.© 2023 Lifshitz Law PLLC. The law firm responsible for this advertisement is Lifshitz Law PLLC, 1190 Broadway, Hewlett, New York 11557, Tel: (516)493-9780. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

    Contact:

    Joshua M. Lifshitz, Esq.

    Lifshitz Law PLLC

    Phone: 516-493-9780

    Facsimile: 516-280-7376

    Email: [email protected] 



    Get the next $APRN alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $APRN
    $ICPT
    $RENB

    CompanyDatePrice TargetRatingAnalyst
    Intercept Pharmaceuticals Inc.
    $ICPT
    7/13/2023$8.00 → $19.00Sell → Buy
    H.C. Wainwright
    Intercept Pharmaceuticals Inc.
    $ICPT
    6/29/2023$12.00 → $18.00Hold → Buy
    Canaccord Genuity
    Intercept Pharmaceuticals Inc.
    $ICPT
    5/23/2023Buy → Hold
    Needham
    Intercept Pharmaceuticals Inc.
    $ICPT
    5/22/2023$8.00Neutral → Sell
    H.C. Wainwright
    Intercept Pharmaceuticals Inc.
    $ICPT
    5/17/2023Outperform → Mkt Perform
    Raymond James
    Blue Apron Holdings Inc.
    $APRN
    8/10/2022$9.00Buy
    Lake Street
    Blue Apron Holdings Inc.
    $APRN
    7/21/2022$10.00Buy
    The Benchmark Company
    Intercept Pharmaceuticals Inc.
    $ICPT
    3/8/2022$31.00 → $29.00Hold
    Canaccord Genuity
    More analyst ratings

    $APRN
    $ICPT
    $RENB
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    AI Just Got a Green Light from the White House--Here's What That Means for Healthcare Stocks

    Equity Insider News CommentaryIssued on behalf of Avant Technologies Inc. VANCOUVER, BC, July 29, 2025 /PRNewswire/ -- Equity Insider News Commentary – There's a lot of big voices pushing for the AI revolution to make its mark, including a new plan from the U.S. Department of Commerce to address slow-to-adopt sectors like healthcare. The comes as part of US President Trump's paper, titled Winning the Race: AMERICA'S AI ACTION PLAN, which encourages setting up regulatory sandboxes, or regulation-free environments where AI can be tested in real world scenarios with heavy oversight. As the market evaluates the opportunities available, several tech and biotech companies are already moving toward

    7/29/25 3:01:00 PM ET
    $GEHC
    $HCTI
    $MDAI
    Medical Electronics
    Health Care
    EDP Services
    Technology

    Smart Healthcare Is Taking Over. Here's Where the Money's Headed

    Issued on behalf of Avant Technologies Inc.Equity Insider News Commentary VANCOUVER, BC, June 10, 2025 /PRNewswire/ -- Both politicians and leaders in academia are touting the AI revolution empowering the frontline of what's dubbed Smart Healthcare. In a recent write-up in Forbes, Prof. Nicos Savva of the London Business School cited recent speeches from former British Prime Minister Tony Blair, who insists that the UK needs to embrace a future with AI doctors and nurses, or risk being left behind. A new report from Wolters Kluwer has experts calling for more clarity around its use, adoption, and business strategy, because most healthcare organizations aren't currently ready to use GenAI too

    6/10/25 11:13:00 AM ET
    $AMZN
    $GOOG
    $GOOGL
    Catalog/Specialty Distribution
    Consumer Discretionary
    Computer Software: Programming Data Processing
    Technology

    Renovaro Secures Key U.S. Patent to Strengthen AI-Driven Drug Discovery and Diagnostics Platform

    Expanded IP Portfolio Enhances Data Harmonization and Predictive Analytics Capabilities for High-Growth Biomedical Markets LOS ANGELES, June 03, 2025 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ:RENB), a clinical-stage precision medicine company, today announced that its subsidiary BioSymetrics has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a new patent application titled "Methods, Systems, and Frameworks for Unbiased Data in Drug Discovery Predictions" (Application No. 18/058,752). This patent strengthens Renovaro's AI and machine learning intellectual property portfolio by protecting novel methods for integrating and harmonizing diverse b

    6/3/25 9:15:00 AM ET
    $RENB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APRN
    $ICPT
    $RENB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    $APRN
    $ICPT
    $RENB
    SEC Filings

    View All

    Intercept Pharma upgraded by H.C. Wainwright with a new price target

    H.C. Wainwright upgraded Intercept Pharma from Sell to Buy and set a new price target of $19.00 from $8.00 previously

    7/13/23 9:10:56 AM ET
    $ICPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Intercept Pharma upgraded by Canaccord Genuity with a new price target

    Canaccord Genuity upgraded Intercept Pharma from Hold to Buy and set a new price target of $18.00 from $12.00 previously

    6/29/23 7:24:17 AM ET
    $ICPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Intercept Pharma downgraded by Needham

    Needham downgraded Intercept Pharma from Buy to Hold

    5/23/23 7:40:07 AM ET
    $ICPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Renovaro Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

    8-K - RENOVARO INC. (0001527728) (Filer)

    8/6/25 11:51:40 AM ET
    $RENB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEF 14A filed by Renovaro Inc.

    DEF 14A - RENOVARO INC. (0001527728) (Filer)

    7/30/25 1:08:53 PM ET
    $RENB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Renovaro Inc. filed SEC Form 8-K: Leadership Update

    8-K - RENOVARO INC. (0001527728) (Filer)

    7/25/25 5:13:37 PM ET
    $RENB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APRN
    $ICPT
    $RENB
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for OCALIVA issued to INTERCEPT PHARMS INC

    Submission status for INTERCEPT PHARMS INC's drug OCALIVA (SUPPL-8) with active ingredient OBETICHOLIC ACID has changed to 'Approval' on 02/24/2022. Application Category: NDA, Application Number: 207999, Application Classification: Labeling

    2/25/22 4:36:46 AM ET
    $ICPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for OCALIVA issued to INTERCEPT PHARMS INC

    Submission status for INTERCEPT PHARMS INC's drug OCALIVA (SUPPL-7) with active ingredient OBETICHOLIC ACID has changed to 'Approval' on 05/26/2021. Application Category: NDA, Application Number: 207999, Application Classification: Labeling

    5/27/21 5:23:24 AM ET
    $ICPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APRN
    $ICPT
    $RENB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Renovaro Inc.

    SC 13D/A - RENOVARO INC. (0001527728) (Subject)

    11/6/24 5:45:52 PM ET
    $RENB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Renovaro Inc.

    SC 13D/A - RENOVARO INC. (0001527728) (Subject)

    10/24/24 8:57:01 AM ET
    $RENB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Renovaro Inc.

    SC 13D/A - RENOVARO INC. (0001527728) (Subject)

    6/24/24 7:56:04 PM ET
    $RENB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APRN
    $ICPT
    $RENB
    Leadership Updates

    Live Leadership Updates

    View All

    Renovaro and BioSymetrics Close Merger to Accelerate AI-Driven Biomarker Discovery and Precision Medicine

    Strategic Combination Intended to Drive Advanced AI-Driven Drug Development and Expand Precision Medicine Applications Across Cancer and Neurology LOS ANGELES, April 09, 2025 (GLOBE NEWSWIRE) -- Renovaro Biosciences Inc. (NASDAQ:RENB), a TechBio leader focused on next-generation diagnostics, drug discovery, and genetically enhanced cancer therapies, today announced it closed its previously announced merger transaction with BioSymetrics, an artificial intelligence (AI)-driven drug discovery and precision neurology company on April 8, 2025. Renovaro's merger with BioSymetrics is designed to enhance Renovaro's data repository and biomarker discovery capabilities, as well as add in vivo vali

    4/9/25 9:25:00 AM ET
    $RENB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sleep Number Board Names Linda Findley as President and Chief Executive Officer

    Findley has a demonstrated record of accelerating growth and transformation across diverse consumer business models Phillip Eyler to become independent Board Chair, effective after the 2025 Annual Meeting of Shareholders Sleep Number Corporation (NASDAQ:SNBR) today announced that its Board of Directors (the "Board") has appointed Linda Findley as the company's new President and Chief Executive Officer, and as a member of the Board, effective April 7, 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250305807579/en/Linda Findley will assume the role of Sleep Number President and CEO on April 7, 2025 (Photo: Business Wire) Fi

    3/5/25 4:15:00 PM ET
    $APRN
    $ETSY
    $RL
    Catalog/Specialty Distribution
    Consumer Discretionary
    Real Estate
    Garments and Clothing

    Renovaro and BioSymetrics Announce Definitive Merger Agreement to Advance AI-Driven Biomarker Discovery and Precision Medicine

    Strategic Combination Aims to Accelerate Biomarker Identification, Enhance Drug Discovery, and Expand Precision Medicine Applications in Cancer and Beyond LOS ANGELES, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Renovaro Biosciences Inc. (NASDAQ:RENB), a TechBio leader focused on next-generation diagnostics, drug discovery, and genetically enhanced cancer therapies, today announced a definitive agreement to merge with BioSymetrics, an artificial intelligence (AI)-driven drug discovery and biomarker identification company. This transformative partnership is designed to enhance Renovaro's data repository, biomarker discovery capabilities, accelerate translational research, and bring precision medicin

    2/26/25 1:25:00 PM ET
    $RENB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APRN
    $ICPT
    $RENB
    Financials

    Live finance-specific insights

    View All

    Blue Apron Announces Agreement to be Acquired by Wonder Group for $13.00 per Share

    Transaction Expected to Create a Leading Platform for Mealtime Focused on Quality and Flavor Across Meal Kits and Fully-Prepared Meal Experiences Blue Apron (NASDAQ:APRN) (the "Company"), the pioneer of the meal kit industry in the United States, today announced that it has entered into a definitive merger agreement to be acquired by Wonder Group ("Wonder"), a company founded by entrepreneur Marc Lore that is redefining at-home dining and food delivery. Under the terms of the merger agreement, which has been unanimously approved by Blue Apron's Board of Directors, Blue Apron stockholders will be entitled to receive $13.00 in cash per share of Class A common stock through a tender offer,

    9/29/23 7:00:00 AM ET
    $APRN
    Catalog/Specialty Distribution
    Consumer Discretionary

    Blue Apron Holdings, Inc. Reports Second Quarter 2023 Results

    Successfully Closes Strategic Transaction with FreshRealm and Eliminates Debt Defines Path to Adjusted EBITDA Profitability With Over 70% Year-over-Year Operating Cash Burn Reduction Blue Apron (NYSE:APRN) today announced financial results for the second quarter (2Q23) ended June 30, 2023. Second Quarter 2023 Highlights Net revenue of $106.2 million, a decrease of 6.1% sequentially and 14.5% year-over-year, largely driven by a one-time $10.0 million bulk sale to an enterprise customer recognized in the second quarter of 2022 (2Q22) and deliberate reduction in marketing spend Record customer engagement metrics, due in part to a price increase implemented in 2Q23 Average Order V

    8/9/23 6:30:00 AM ET
    $APRN
    Catalog/Specialty Distribution
    Consumer Discretionary

    Intercept to Announce Second Quarter 2023 Financial Results on August 2, 2023

    MORRISTOWN, N.J., July 26, 2023 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare and serious liver diseases, will announce its second quarter 2023 financial results on Wednesday, August 2, 2023. The announcement will be followed by a conference call and audio webcast at 8:30 a.m. ET. Participants can access the conference call live via webcast which will be available on the investor page of the company's website at http://ir.interceptpharma.com. Participants who wish to ask a question may register here to receive dial-in numbers and a unique pin to join the

    7/26/23 8:00:00 AM ET
    $ICPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APRN
    $ICPT
    $RENB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner William Anderson Wittekind disposed of 350,000 shares, decreasing direct ownership by 9% to 3,353,878 units (SEC Form 4)

    4 - RENOVARO INC. (0001527728) (Issuer)

    3/12/25 8:12:50 AM ET
    $RENB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Van Tilburg Maurice was granted 250,000 shares (SEC Form 4)

    4 - RENOVARO INC. (0001527728) (Issuer)

    2/25/25 1:33:34 PM ET
    $RENB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chief Financial Officer Fuentes Nathen

    4 - RENOVARO INC. (0001527728) (Issuer)

    2/25/25 1:29:46 PM ET
    $RENB
    Biotechnology: Pharmaceutical Preparations
    Health Care